<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32409664</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-4889</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell death &amp; disease</Title><ISOAbbreviation>Cell Death Dis</ISOAbbreviation></Journal><ArticleTitle>HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo.</ArticleTitle><Pagination><StartPage>369</StartPage><MedlinePgn>369</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">369</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41419-020-2580-3</ELocationID><Abstract><AbstractText>TDP-43 pathology is a disease hallmark that characterizes both amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP). TDP-43 undergoes several posttranslational modifications that can change its biological activities and its aggregative propensity, which is a common hallmark of different neurodegenerative conditions. New evidence is provided by the current study pointing at TDP-43 acetylation in ALS cellular models. Using both in vitro and in vivo approaches, we demonstrate that TDP-43 interacts with histone deacetylase 1 (HDAC1) via RRM1 and RRM2 domains, that are known to contain the two major TDP-43 acetylation sites, K142 and K192. Moreover, we show that TDP-43 is a direct transcriptional activator of CHOP promoter and this activity is regulated by acetylation. Finally and most importantly, we observe both in cell culture and in Drosophila that a HDCA1 reduced level (genomic inactivation or siRNA) or treatment with pan-HDAC inhibitors exert a protective role against WT or pathological mutant TDP-43 toxicity, suggesting TDP-43 acetylation as a new potential therapeutic target. HDAC inhibition efficacy in neurodegeneration has long been debated, but future investigations are warranted in this area. Selection of more specific HDAC inhibitors is still a promising option for neuronal protection especially as HDAC1 appears as a downstream target of both TDP- 43 and FUS, another ALS-related gene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanna</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esposito</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masala</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieddu</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galioto</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fais</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Ciro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cestra</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istitute of Molecular Biology and Pathology-National Research Council at Department of Biology and Biotechnology-Charles Darwin, Sapienza University of Rome, P.Le A.Moro 5, I-00185, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crosio</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2452-1145</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Sassari, Via Muroni 25, I-07100, Sassari, Italy. ccrosio@uniss.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Death Dis</MedlineTA><NlmUniqueID>101524092</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="C484389">Hdac1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D056284">Histone Deacetylase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056284" MajorTopicYN="N">Histone Deacetylase 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors disclose any financial and personal relationships with other people or organisations that could inappropriately influence our work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32409664</ArticleId><ArticleId IdType="pmc">PMC7224392</ArticleId><ArticleId IdType="doi">10.1038/s41419-020-2580-3</ArticleId><ArticleId IdType="pii">10.1038/s41419-020-2580-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berning BA, Walker AK. The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335. doi: 10.3389/fnins.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Cenik B, Cenik BK, Herz J, Yu G. TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration. Biol. Chem. 2012;393:589&#x2013;594. doi: 10.1515/hsz-2012-0115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2012-0115</ArticleId><ArticleId IdType="pmc">PMC3537500</ArticleId><ArticleId IdType="pubmed">22944662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Dormann D. TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett. 2017;591:1489&#x2013;1507. doi: 10.1002/1873-3468.12646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12646</ArticleId><ArticleId IdType="pubmed">28380257</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Rademakers R, Petrucelli L. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J. Alzheimers Dis. 2013;33(Suppl 1):S35&#x2013;S45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3532959</ArticleId><ArticleId IdType="pubmed">22751173</ArticleId></ArticleIdList></Reference><Reference><Citation>French RL, et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J. Biol. Chem. 2019;294:6696&#x2013;6709. doi: 10.1074/jbc.RA118.005889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005889</ArticleId><ArticleId IdType="pmc">PMC6497947</ArticleId><ArticleId IdType="pubmed">30824544</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 2015;6:5845. doi: 10.1038/ncomms6845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6845</ArticleId><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Wander CM, Yuan CX, Bereman MS, Cohen TJ. Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program. Nat. Commun. 2017;8:82. doi: 10.1038/s41467-017-00088-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00088-4</ArticleId><ArticleId IdType="pmc">PMC5517419</ArticleId><ArticleId IdType="pubmed">28724966</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y, Cavalli V. HDAC signaling in neuronal development and axon regeneration. Curr. Opin. Neurobiol. 2014;27:118&#x2013;126. doi: 10.1016/j.conb.2014.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2014.03.008</ArticleId><ArticleId IdType="pmc">PMC4122610</ArticleId><ArticleId IdType="pubmed">24727244</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32:591&#x2013;601. doi: 10.1016/j.tins.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2009.06.002</ArticleId><ArticleId IdType="pmc">PMC2771446</ArticleId><ArticleId IdType="pubmed">19775759</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle C, et al. Tissue-specific deregulation of selected HDACs characterizes ALS progression in mouse models: pharmacological characterization of SIRT1 and SIRT2 pathways. Cell Death Dis. 2014;5:e1296. doi: 10.1038/cddis.2014.247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2014.247</ArticleId><ArticleId IdType="pmc">PMC4611720</ArticleId><ArticleId IdType="pubmed">24946089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SA, Tanaz R, Cobos SN, Torrente MP. Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease. Transl. Res. 2019;204:19&#x2013;30. doi: 10.1016/j.trsl.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2018.10.002</ArticleId><ArticleId IdType="pmc">PMC6331271</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XJ, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr. Opin. Genet Dev. 2003;13:143&#x2013;153. doi: 10.1016/S0959-437X(03)00015-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-437X(03)00015-7</ArticleId><ArticleId IdType="pubmed">12672491</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Myers SJ, Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 1999;2:867&#x2013;872. doi: 10.1038/13165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/13165</ArticleId><ArticleId IdType="pubmed">10491605</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen C, et al. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2010;69:573&#x2013;581. doi: 10.1097/NEN.0b013e3181ddd404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181ddd404</ArticleId><ArticleId IdType="pubmed">20467334</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardai FH, Price V, Zaayman M, Wang L, D&#x2019;Mello SR. Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J. Biol. Chem. 2012;287:35444&#x2013;35453. doi: 10.1074/jbc.M112.394544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394544</ArticleId><ArticleId IdType="pmc">PMC3471765</ArticleId><ArticleId IdType="pubmed">22918830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 2010;13:180&#x2013;189. doi: 10.1038/nn.2471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2471</ArticleId><ArticleId IdType="pmc">PMC2829989</ArticleId><ArticleId IdType="pubmed">20037577</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WY, et al. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 2013;16:1383&#x2013;1391. doi: 10.1038/nn.3514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3514</ArticleId><ArticleId IdType="pmc">PMC5564396</ArticleId><ArticleId IdType="pubmed">24036913</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu H, et al. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Invest. 2014;124:981&#x2013;999. doi: 10.1172/JCI72723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI72723</ArticleId><ArticleId IdType="pmc">PMC3938263</ArticleId><ArticleId IdType="pubmed">24509083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill SJ, et al. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc. Natl Acad. Sci. USA. 2016;113:E7701&#x2013;E7709. doi: 10.1073/pnas.1611673113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1611673113</ArticleId><ArticleId IdType="pmc">PMC5137757</ArticleId><ArticleId IdType="pubmed">27849576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra, J. et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci USA, 10.1073/pnas.1818415116. (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004. doi: 10.1016/j.cell.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbes L, Riessland M, Wirth B. Histone acetylation as a potential therapeutic target in motor neuron degenerative diseases. Curr. Pharm. Des. 2013;19:5093&#x2013;5104. doi: 10.2174/13816128113199990356.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/13816128113199990356</ArticleId><ArticleId IdType="pubmed">23448465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc. Natl Acad. Sci. USA. 2008;105:3785&#x2013;3789. doi: 10.1073/pnas.0800546105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800546105</ArticleId><ArticleId IdType="pmc">PMC2268791</ArticleId><ArticleId IdType="pubmed">18305152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs G, et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov. Disord. 2009;24:1843&#x2013;1847. doi: 10.1002/mds.22697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22697</ArticleId><ArticleId IdType="pubmed">19609911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 1995;69:3584&#x2013;3596. doi: 10.1128/JVI.69.6.3584-3596.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.6.3584-3596.1995</ArticleId><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalmansingh AS, Urekar CJ, Reddi PP. TDP-43 is a transcriptional repressor: the testis-specific mouse acrv1 gene is a TDP-43 target in vivo. J. Biol. Chem. 2011;286:10970&#x2013;10982. doi: 10.1074/jbc.M110.166587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.166587</ArticleId><ArticleId IdType="pmc">PMC3064152</ArticleId><ArticleId IdType="pubmed">21252238</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddi PP. Transcription and splicing factor TDP-43: role in regulation of gene expression in testis. Semin Reprod. Med. 2017;35:167&#x2013;172. doi: 10.1055/s-0037-1599088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1599088</ArticleId><ArticleId IdType="pubmed">28278534</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Matsuoka M. TDP-43 toxicity is mediated by the unfolded protein response-unrelated induction of C/EBP homologous protein expression. J. Neurosci. Res. 2012;90:641&#x2013;647. doi: 10.1002/jnr.22777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22777</ArticleId><ArticleId IdType="pubmed">22057717</ArticleId></ArticleIdList></Reference><Reference><Citation>Masala A, et al. Epigenetic changes associated with the expression of amyotrophic lateral sclerosis (ALS) causing genes. Neuroscience. 2018;390:1&#x2013;11. doi: 10.1016/j.neuroscience.2018.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.08.009</ArticleId><ArticleId IdType="pubmed">30134203</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250. doi: 10.1371/journal.pone.0013250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013250</ArticleId><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102:339&#x2013;357 e337. doi: 10.1016/j.neuron.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;338 e328. doi: 10.1016/j.neuron.2019.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis. Model Mech. 2017;10:537&#x2013;549. doi: 10.1242/dmm.029058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.029058</ArticleId><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna V, et al. Single-step green synthesis and characterization of gold-conjugated polyphenol nanoparticles with antioxidant and biological activities. Int J. Nanomed. 2014;9:4935&#x2013;4951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4211914</ArticleId><ArticleId IdType="pubmed">25364251</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006;22:40&#x2013;49. doi: 10.1016/j.nbd.2005.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.09.013</ArticleId><ArticleId IdType="pubmed">16289867</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014;13:673&#x2013;691. doi: 10.1038/nrd4360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4360</ArticleId><ArticleId IdType="pubmed">25131830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005;93:1087&#x2013;1098. doi: 10.1111/j.1471-4159.2005.03077.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03077.x</ArticleId><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler. 2009;10:99&#x2013;106. doi: 10.1080/17482960802320487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802320487</ArticleId><ArticleId IdType="pubmed">18688762</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo YE, Ko CP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2011;231:147&#x2013;159. doi: 10.1016/j.expneurol.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.06.003</ArticleId><ArticleId IdType="pubmed">21712032</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006;7:784&#x2013;796. doi: 10.1038/nrn1989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1989</ArticleId><ArticleId IdType="pubmed">16988654</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. A Drosophila model for TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA. 2010;107:3169&#x2013;3174. doi: 10.1073/pnas.0913602107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId><ArticleId IdType="pmc">PMC2840283</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgio G, Cipressa F, Ingrassia AM, Cenci G, Corona DF. The histone deacetylase Rpd3 regulates the heterochromatin structure of Drosophila telomeres. J. Cell Sci. 2011;124:2041&#x2013;2048. doi: 10.1242/jcs.078261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.078261</ArticleId><ArticleId IdType="pubmed">21625008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, et al. Atrophin-Rpd3 complex represses Hedgehog signaling by acting as a corepressor of CiR. J. cell Biol. 2013;203:575&#x2013;583. doi: 10.1083/jcb.201306012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201306012</ArticleId><ArticleId IdType="pmc">PMC3840934</ArticleId><ArticleId IdType="pubmed">24385484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y. Axon injury induced endoplasmic reticulum stress and neurodegeneration. Neural Regen. Res. 2016;11:1557&#x2013;1559. doi: 10.4103/1673-5374.193225.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.193225</ArticleId><ArticleId IdType="pmc">PMC5116825</ArticleId><ArticleId IdType="pubmed">27904477</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL. Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol. 2015;11:266&#x2013;279. doi: 10.1038/nrneurol.2015.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita T, Weinert BT, Choudhary C. Functions and mechanisms of non-histone protein acetylation. Nat. Rev. Mol. Cell Biol. 2019;20:156&#x2013;174. doi: 10.1038/s41580-018-0081-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0081-3</ArticleId><ArticleId IdType="pubmed">30467427</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat. Genet. 2012;44:1302&#x2013;1309. doi: 10.1038/ng.2434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2434</ArticleId><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht Gopal YN, Arora TS, Van Dyke MW. Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2. EMBO Rep. 2006;7:291&#x2013;296. doi: 10.1038/sj.embor.7400613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400613</ArticleId><ArticleId IdType="pmc">PMC1456891</ArticleId><ArticleId IdType="pubmed">16374504</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, et al. Subcellular distribution of HDAC1 in neurotoxic conditions is dependent on serine phosphorylation. J. Neurosci. 2017;37:7547&#x2013;7559. doi: 10.1523/JNEUROSCI.3000-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3000-16.2017</ArticleId><ArticleId IdType="pmc">PMC5546117</ArticleId><ArticleId IdType="pubmed">28663197</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, et al. Subcellular localization of class I histone deacetylases in the developing xenopus tectum. Front Cell Neurosci. 2015;9:510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4709447</ArticleId><ArticleId IdType="pubmed">26793062</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35:1077&#x2013;1097. doi: 10.15252/embj.201592559.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201592559</ArticleId><ArticleId IdType="pmc">PMC4868956</ArticleId><ArticleId IdType="pubmed">26951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahnen E, et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs. 2008;17:169&#x2013;184. doi: 10.1517/13543784.17.2.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.17.2.169</ArticleId><ArticleId IdType="pubmed">18230051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouaux C, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 2007;27:5535&#x2013;5545. doi: 10.1523/JNEUROSCI.1139-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1139-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672753</ArticleId><ArticleId IdType="pubmed">17522299</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R. D. 2011;11:227&#x2013;249. doi: 10.2165/11591280-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11591280-000000000-00000</ArticleId><ArticleId IdType="pmc">PMC3586072</ArticleId><ArticleId IdType="pubmed">21902286</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosio C, Valle C, Casciati A, Iaccarino C, Carri MT. Astroglial inhibition of NF-kappaB does not ameliorate disease onset and progression in a mouse model for amyotrophic lateral sclerosis (ALS) PLoS ONE. 2011;6:e17187. doi: 10.1371/journal.pone.0017187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017187</ArticleId><ArticleId IdType="pmc">PMC3060799</ArticleId><ArticleId IdType="pubmed">21445241</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepers S, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 2009;66:227&#x2013;234. doi: 10.1002/ana.21620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21620</ArticleId><ArticleId IdType="pubmed">19743466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigna E, et al. Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis. EBioMedicine. 2019;40:717&#x2013;732. doi: 10.1016/j.ebiom.2019.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.01.038</ArticleId><ArticleId IdType="pmc">PMC6414308</ArticleId><ArticleId IdType="pubmed">30713114</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossaert E, et al. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathol. Commun. 2019;7:107. doi: 10.1186/s40478-019-0750-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0750-2</ArticleId><ArticleId IdType="pmc">PMC6612190</ArticleId><ArticleId IdType="pubmed">31277703</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong J, et al. RBM45 competes with HDAC1 for binding to FUS in response to DNA damage. Nucleic Acids Res. 2017;45:12862&#x2013;12876. doi: 10.1093/nar/gkx1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1102</ArticleId><ArticleId IdType="pmc">PMC5728411</ArticleId><ArticleId IdType="pubmed">29140459</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutillier A-L, Tzeplaeff L, Dupuis L. The dark side of HDAC inhibition in ALS. EBioMedicine. 2019;40:38&#x2013;39. doi: 10.1016/j.ebiom.2019.02.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.02.039</ArticleId><ArticleId IdType="pmc">PMC6443023</ArticleId><ArticleId IdType="pubmed">30803935</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuff, T. et al. Drosophila models of pathogenic copy-number variant genes show global and 1 non-neuronal defects during development. BioRxiv. 10.1101/855338 (2019).</Citation></Reference><Reference><Citation>Yusuff, T., Chatterjee, S., Chang, Y.-C., Sang, T.-K. &amp; Jackson, G. R. Codon-optimized TDP-43-mediated neurodegeneration in a Drosophila model for ALS/FTLD. bioRxiv. 696963, 10.1101/696963 (2019).</Citation></Reference><Reference><Citation>Di Salvio M, et al. Pur-alpha functionally interacts with FUS carrying ALS-associated mutations. Cell Death Dis. 2015;6:e1943. doi: 10.1038/cddis.2015.295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.295</ArticleId><ArticleId IdType="pmc">PMC4632316</ArticleId><ArticleId IdType="pubmed">26492376</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, et al. Redox-sensitive GFP to monitor oxidative stress in neurodegenerative diseases. Rev. Neurosci. 2017;28:133&#x2013;144. doi: 10.1515/revneuro-2016-0041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2016-0041</ArticleId><ArticleId IdType="pubmed">28030361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepedda AJ, et al. Identification of differentially expressed plasma proteins in atherosclerotic patients with type 2 diabetes. J. Diabetes Complications. 2016;30:880&#x2013;886. doi: 10.1016/j.jdiacomp.2016.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2016.03.007</ArticleId><ArticleId IdType="pubmed">27037039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepedda AJ, et al. Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker. Oxid. Med Cell Longev. 2013;2013:385214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886437</ArticleId><ArticleId IdType="pubmed">24454983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruhat A, et al. Amino acids control mammalian gene transcription: activating transcription factor 2 is essential for the amino acid responsiveness of the CHOP promoter. Mol. Cell Biol. 2000;20:7192&#x2013;7204. doi: 10.1128/MCB.20.19.7192-7204.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.20.19.7192-7204.2000</ArticleId><ArticleId IdType="pmc">PMC86273</ArticleId><ArticleId IdType="pubmed">10982836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013;8:2281&#x2013;2308. doi: 10.1038/nprot.2013.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>